Drugs / ONCOFID P-B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04798703 | May 2017 → May 2020 | bladder carcinoma in situ | Fidia Farmaceutici s.p.a. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05024773 | Dec 2022 → May 2028 expected | bladder carcinoma in situ | Fidia Farmaceutici s.p.a. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONCOFID P-B | “Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)” NCT05024773 ↗ |
| Known as | PACLITAXEL-HYALURONIC ACID | “Drug: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)” NCT05024773 ↗1“ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)” NCT04798703 ↗ |
| Modality | Other / unclassified | “ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate)” NCT05024773 ↗ |
| Route | Other | “12 weekly intravesical instillations of ONCOFID-P-B™” NCT04798703 ↗ |